• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ARAV

ARAV

Aravive, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.04

-0.01 (-13.39%)

Company Profile

CEO

Fredric N. Eshelman

IPO Date

2014-03-21

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.04

Prev. Close

$0.05

Day Low

$0.04

Day High

$0.05

52W Low

$0.04

52W High

$2.46

Market Cap

$0.00B

Volume

4.04M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

13.5%

Avg Negative

2.4%

Avg Neutral

83.8%

News Feed

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

GlobeNewsWire·7/27/2021·↑ positive

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

GlobeNewsWire·7/7/2021·↑ positive

Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting

GlobeNewsWire·3/12/2021·↑ positive

Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market

GlobeNewsWire·2/16/2021·↑ positive

Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference

GlobeNewsWire·1/4/2021·↑ positive

Aravive Announces Board Member Transition to Advisory Role

GlobeNewsWire·12/31/2020·↓ negative

Aravive Biologics: Pipeline-In-A-Pill In Oncology

Seeking Alpha·12/28/2020·↑ positive

Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

GlobeNewsWire·11/10/2020·↑ positive

Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

GlobeNewsWire·11/5/2020·↑ positive